The council in a illustration to BVR Subrahmanyam, Secretary, Ministry of Commerce, lately, mentioned, “This will permit the producers to export surplus manufacturing to different international locations in order that international locations and sufferers in want of these injections can profit from the identical provides in a well timed method. In a situation, the place there’s a peak in affected person load/circumstances in India, the mentioned restriction on export of these merchandise could be reintroduced.”
The removal of restriction on remdesivir and amphotericin-B exports not only benefits the patients across the globe, it would also facilitate the industry to reach the overall export target of US$ 400 billion set by the Prime Minister and a target of US$ 29 billion set for the pharma sector, it said.
The council has also sent representation to Amit Yadav, director general, Directorate General of Foreign Trade (DGFT), S Aparna, secretary, Department of Pharmaceuticals (DoP), Rajesh Bhushan, secretary, ministry of health & family welfare in this regard.
To ensure the availability of these medicines to the needy patients during the second wave of COVID in the country, DGFT had put in place export restrictions for remdesivir and amphotericin B injections vide notifications dated June 14, 2021 and June 1, 2021 respectively.
The second wave of COVID there was a huge demand for remdesivir injections as well as for antifungal medicine ‘amphotericin B’ injection required for treatment of mucormycosis.
To meet domestic demand, a number of manufacturers and importers with permission from DCG(I) scaled up their production and bolstered India’s production capacity of remdesivir and amphotericin-B injections. At present India is well stoked to meet any emergency demand for the said medicaments.
Earlier, on August 23, 2021 Pharmexcil had submitted a detailed representation with a request for relaxation for exports of remdesivir injections.